That data is immensely valuable in helping scientists more quickly decipher the genes from the genome sequence data that is now available. Genes, which are broken into pieces and buried among the three billion letters, comprise roughly five percent of the genome. These transcribed genes, or messenger RNA, are then translated into specific proteins that carry out most of the functions of the human body. Over the last decade, scientists around the world have been using this information to accelerate their efforts for developing safer, more effective treatments for disease. Because we have been working with transcribed genes, we can provide researchers with physical copies of the genes, or clones, in our databases.
Clones are an invaluable resource for scientists who want to conduct further lab research.
The resources we have developed provide researchers with a comprehensive solution for understanding the molecular basis of disease. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.